Format

Send to

Choose Destination
See comment in PubMed Commons below
Psychiatr Serv. 2008 Mar;59(3):315-7. doi: 10.1176/appi.ps.59.3.315.

Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.

Author information

1
Eli Lilly and Company, Lilly Corporate Center Drop 4133, Indianapolis, IN 46285, USA.

Abstract

OBJECTIVE:

This study compared the time to discontinuation for any reason of first-generation antipsychotics--in oral versus depot formulation--in the usual care of schizophrenia.

METHODS:

This study used data from a three-year, prospective, nonrandomized, noninterventional, multisite study of schizophrenia. Participants initiated on oral haloperidol or fluphenazine (N=202) were compared with those initiated on haloperidol or fluphenazine in depot formulation (N=97) on time to all-cause discontinuation for one year after initiation, by using Kaplan-Meier survival analysis, a Cox proportional hazards regression model, and propensity score-adjusted bootstrap resampling methods.

RESULTS:

Compared with participants treated with the oral formulation, those treated with depot first-generation antipsychotics had a significantly longer mean time to all-cause medication discontinuation and were twice as likely to stay on the medication.

CONCLUSION:

In the usual care of schizophrenia, treatment with first-generation antipsychotics in depot formulation appears to be associated with longer time to all-cause medication discontinuation compared with oral formulation of the same medication.

PMID:
18308914
DOI:
10.1176/ps.2008.59.3.315
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center